If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal ...

Novo Nordisk A/S (NYSE: NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Popular digital weight loss app, Noom (NOOM) undercuts Novo Nordisk's Wegovy by offering quarter-dose packs at $119 for the ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

The Microdose GLP-1Rx Program will offer low-dose GLP-1 prescriptions combined with behavioral coaching, clinical monitoring and medication management.

With 14 new lawsuits filed and 132 total complaints across 40 states, Novo Nordisk is intensifying efforts to protect ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Danish diabetes and obesity giant Novo Nordisk has announced the filing of 14 new lawsuits to safeguard patients from unsafe ...

These growth stocks come from completely different industries, but each has something to offer long-term investors.

Gibbs Mura encourages investors to contact us about their legal rights and options in the Hims & Hers Health, Inc. (NYSE: HIMS) Securities Class Action Lawsuit . What Should Hims & Hers Investors Do?